India’s World-Class Biological Drugs Testing Center Sits Largely Unused
This article was originally published in PharmAsia News
Executive Summary
India's government built a set of world-class laboratories to serve as the central source for testing biotech drugs, but although it has had labs completed and opened since 2000, it has tested few drugs. The National Institute of Biologicals was ordered built in the early nineties and declared by law to serve as the testing center at the beginning of a biologicals wave. Since then, 350 biological drugs have entered the market, but few were tested at the lab, even though the huge facility was completed last year. Intended to house 85 scientists and 115 technicians, the NIB today is staffed by only nine scientists and a dozen or so technicians. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.